Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

helping reduce the symptoms of cystic fibrosis. However, these medications are only effective in people with specific CFTR mutations. Therefore, doctors will choose the type of CTFR modulator ...

A Waltham biotech focused on cystic fibrosis and a Boston biotech led by serial founder Gary Glick are the first ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction ...

An additional 94 non-F508del CFTR mutations and a boxed warning on liver injury and liver failure were included in the updated prescribing information. 1507_1515del9, 2183A→G, A1067P ...

As Healio previously reported, the FDA recently approved Alyftrek for patients aged 6 years and older with cystic fibrosis with certain mutations ... to further restore CFTR function in a broader ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction representing a critical and ...

While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

Boehringer Ingelheim (BI) and the UK Cystic Fibrosis Gene Therapy Consortium ... therapeutic approach to date that can address all CFTR gene mutations and holding a potential for a universal ...